Heilicobacter pylori infection
Conditions
Interventions
experimental group(low dose tetracycline):Tetracycline 500 mg bid+amoxicillin 1000 mg bid+Rabeprazole 10mg bid+Bismuth potassium citrate 600mg/Colloidal bismuth pectin 200mg bid
control group(conventional dose tetracycline):Tetracycline 500 mg tid+amoxicillin 1000 mg bid+Rabeprazole 10mg bid+Bismuth potassium citrate 600mg/Colloidal bismuth pectin 200mg bid
Sponsors
Sir Run Run Shaw Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70. 2. Patients with H.pylori infection(positive for 13C-urease breath test or gastric mucosal biopsy), who have done the gastroscopy within the last month. 3. Patients who have never received regular H. pylori eradication treatment. 4. Ability and willingness to participate in the study and to sign and give informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have received Helicobacter pylori eradication treatment. 2. Patients who are allergic or have contradictions to the drugs for research. 3. Major systemic diseases, such as pulmonary disease, cardiovascular disease, and severe endocrine disease. 4. Continuous use of anti-ulcer drugs (more than 3 times per month), including proton pump inhibitors (PPI), antibiotics or bismuth within 2 weeks before C13-urease breath test or gastric mucosa biopsy. 5. Lactating women. 6. History of upper gastrointestinal surgery. 7. Patients who have Barrett's esophagus or high atypical hyperplasia with dysphagia symptoms. 8. History of malignant tumors. 9. History of drug or alcohol abuse in the past 1 year. 10. Systematic use of corticosteroids, non-steroidal anti-inflammatory drugs, anticoagulants, or platelet aggregation inhibitors (except for the use of aspirin with less than 100 mg/day) 11. Enrolled in other clinical trials in the past 3 months. 12. Patients with poor compliance. 13. Vulnerable groups, including those with mental disease, cognitive impairment or critical disease and juveniles, pregnant women, illiterates, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom remission rate;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactHu Weiling
Department of Gastroenterology, Sir Run Run Shaw Hospital
Outcome results
None listed